glp 1 compound fda Compounded GLP-1s: Why doctors worry and the is cracking down Novo pressures GLP-1 compounders as

In contrast, CNS, but not vagal, GLP-1Rs were required for a complete anorectic response to the long-acting GLP-1R agonist liraglutide and the anorectic and weight loss effects of chronic liraglutide treatment

Semaglutide received FDA clearance for adolescent use (ages 12+) in late 2023, but only for patients with severe obesity and significant metabolic or cardiovascular risk factors, and always under strict medical supervision

The treatment targets areas of the brain that regulate appetite, which allows for more profound control over food intake

doi: 10.1111/bph.15508, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 71.McClean PL, Parthsarathy V, Faivre E, Holscher C

research and clinical opportunities to address weight stigma and foster health equity have been proposed [232]

But their impact is set to extend far beyond just blood sugar control